1. The Management of Diabetic Neuropathy in CKD
Rodica Pop-Busui, MD, PhD, Laurel Roberts, BS, Subramaniam Pennathur, MD, Mathias Kretzler, MD, Frank C. Brosius, MD, Eva L. Feldman, MD, PhD 
American Journal of Kidney Diseases 
Volume 55, Issue 2, Pages (February 2010)
DOI: /j.ajkd
Copyright © 2010 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Proposed paradigm of the mechanisms inducing neurotoxicity in diabetic patients with chronic kidney disease (CKD). Abbreviations: AGE, advanced glycation end products; GSH, glutathione; GSSG, oxidized glutathione; NADP, nicotinamide adenine dinucleotide phosphate; NADPH, reduced NADP; NF-κB, nuclear factor κB; PAI 1, plasminogen activator inhibitor 1; PARP, poly(ADP-ribose) polymerase; PKC, protein kinase C; PTH, parathyroid hormone; RNS, reactive nitrogen species; ROS, reactive oxygen species; SDH, sorbitol dehygrogenase; TCA, tricarboxylic acid; VEGF, vascular endothelial growth factor. Adapted and reproduced from Edwards et al23 with permission of Elsevier.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2010 National Kidney Foundation, Inc. Terms and Conditions